Residual tumor after primary excision of ductal carcinoma in situ (DCIS), on re-excision specimens

被引:0
作者
Nistor-Ciurba, C. C. [1 ,2 ]
机构
[1] Prof Dr Ion Chiricuta Oncol Inst, Dept Surg Oncol, Cluj Napoca 400015, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Dept Surg & Gynecol Oncol, Cluj Napoca, Romania
关键词
ductal carcinoma in situ (DCIS); residual tumor; resection margins; mastectomy; local excision; BREAST-CONSERVING SURGERY; SURGICAL ADJUVANT BREAST; LOCAL RECURRENCE; CANCER; TAMOXIFEN; RADIOTHERAPY; EXPRESSION; OUTCOMES; MARKER; NSABP;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The management of pure ductal carcinoma in situ (DCIS) involves local excision, with or without consecutive radiotherapy, or simple mastectomy. Assessment of the recurrence risk is the essential step in decision-making. The hypothesis of this study was that besides the apparition of true recurrences after prior complete excision there may be also cases with residual disease present distant from the initial excised lesion (more than 2 mm). The last ones could be better considered as being cases of evolving disease. To evaluate the presence of residual disease in the re-excision specimens derived either from mastectomies or wide local re-excisions, a cohort of 102 cases of DCISs, operated in "Prof. Dr. Ion Chiricuta" Oncology Institute, Cluj-Napoca, Romania, between 2000 and 2007, were studied. The presence of residual tumor in re-excision specimens was correlated with high grade of DCIS and with age of the patient (less than 60 years). The analysis of mastectomy specimens revealed that 35.4% of all mastectomies had no residual disease (unnecessary mastectomies). Moreover, 59.8% of them had no residual disease or only close residual disease, virtually curable by simple re-excision. This study suggests that up to 59.8% of mastectomies could be avoided. Important is to select those cases in which avoiding mastectomy may be done assuming an acceptable recurrence risk. The study shows that those cases are from over 60-year-old group and those having histological grade G1. Larger prospective studies are needed to confirm the results of this study.
引用
收藏
页码:821 / 825
页数:5
相关论文
共 22 条
  • [11] Ductal carcinoma in situ, complexities and challenges
    Leonard, GD
    Swain, SM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (12): : 906 - 920
  • [12] Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
    Mallett, S.
    Timmer, A.
    Sauerbrei, W.
    Altman, D. G.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (01) : 173 - 180
  • [13] The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast
    Neuschatz, AC
    DiPetrillo, T
    Steinhoff, M
    Safaii, H
    Yunes, M
    Landa, M
    Chung, M
    Cady, B
    Wazer, DE
    [J]. CANCER, 2002, 94 (07) : 1917 - 1924
  • [14] Ductal carcinoma in situ - Current management
    O'Sullivan, Martin J.
    Morrow, Monica
    [J]. SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (02) : 333 - +
  • [15] In patients with DCIS: is it sufficient to histologically examine only those tissue specimens that contain microcalcifications?
    Poellinger, Alexander
    Diekmann, Susanne
    Dietz, Ekkehart
    Bick, Ulrich
    Diekmann, Felix
    [J]. EUROPEAN RADIOLOGY, 2008, 18 (05) : 925 - 930
  • [16] Significance of multifocality in ductal carcinoma in situ: Outcomes of women treated with breast-conserving therapy
    Rakovitch, Eileen
    Pignol, Jean-Philippe
    Hanna, Wedad
    Narod, Steven
    Spayne, Jacqueline
    Nofech-Mozes, Sharon
    Chartier, Carole
    Paszat, Lawrence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5591 - 5596
  • [17] Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ
    Rudloff, Udo
    Jacks, Lindsay M.
    Goldberg, Jessica I.
    Wynveen, Christine A.
    Brogi, Edi
    Patil, Sujata
    Van Zee, Kimberly J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3762 - 3769
  • [18] Silverstein Melvin J, 2003, Oncology (Williston Park), V17, P1511
  • [19] Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO
  • [20] 2-V